BridgeBio Pharma BBIO Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's change in accrued liabilities?
- BridgeBio Pharma (BBIO) reported change in accrued liabilities of -$37.48M in Q1 2026.
- How has BridgeBio Pharma's change in accrued liabilities changed year-over-year?
- BridgeBio Pharma's change in accrued liabilities decreased by 93.5% year-over-year, from -$19.36M to -$37.48M.
- What does change in accrued liabilities mean?
- The change in expenses incurred but not yet paid by the company.
- How do you interpret change in accrued liabilities?
- An increase in accruals preserves cash in the short term, while a decrease represents a cash outflow as obligations are settled.
- How does change in accrued liabilities compare across companies?
- Standard across all industries; reflects the company's operational scale and expense recognition timing.